🔎 Trials Near Me

Utama › Dermatomiositis › Massachusetts

Kajian klinikal Dermatomiositis di Massachusetts

5 kajian untuk Dermatomiositis sedang mencari peserta di lokasi di Massachusetts.

Bandar di Massachusetts

Teks kajian rasmi (Bahasa Inggeris)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  • Research Site, Boston
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06455449

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
Mengambil pesertaFasa 2/3
Umur 6 hingga 75 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06154252

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  • Brigham and Women's Hospital, Boston
  • CTC - Brigham & Women's Hospital, Boston
  • CTH - Brigham & Women's Hospital, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT05895786

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  • Brigham And Womens Hospital, Boston
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT07115745

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.